Abstract

Hydroquinone (HQ) is one of the most frequently used and effective skin-lightening products to treat skin hyperpigmentation disorders, including postinflammatory hyperpigmentation, melasma and solar lentigines. HQ is also widely used in cosmetic products for skin whitening. However, HQ treatment can evoke substantial skin irritation, a side effect that remains poorly understood. Here we demonstrate that HQ is an activator of the peripheral irritant receptor transient receptor potential (TRP) cation channel member A1 (TRPA1). HQ failed to activate TRPV1, TRPV4 or TRPM8. HQ-induced TRPA1 activation was dependent on essential redox-sensitive cysteine and lysine residues within N-terminus of channel protein. HQ elicited Ca2+ influx in a subpopulation of mouse sensory neurons sensitive to the TRPA1 agonist, mustard oil. HQ-induced neuronal responses were significantly reduced by TRPA1 inhibitors, and reduced in neurons isolated from Trpa1-deficient mice. In mice, intraplantar injection of HQ at clinically relevant concentrations elicited both acute pain and persistent mechanical hyperalgesia which were almost completely abolished by TRPA1 inhibitors. These findings identify TRPA1 as a molecular target for HQ and provide insights into the mechanism of HQ-induced skin irritation. These findings also suggest that selective TRPA1 antagonists may be useful to counteract HQ-induced skin irritation.

Highlights

  • Treatments with >4% HQ are only available by prescription[4, 5]

  • We aimed to explore whether HQ could act as an activator of the irritation/pain-sensing TRPA1 or TRPV1 ion channels in vitro

  • Live cell Ca2+ imaging was used to investigate the effects of HQ on Human embryonic kidney (HEK) 293 cells expressing either human TRPA1 or human TRPV1

Read more

Summary

Introduction

Treatments with >4% HQ are only available by prescription[4, 5]. HQ remains the gold standard treatment for PIH, melasma and solar lentigines[3, 4]. Topical HQ often causes local irritation, including burning, pruritus and erythema[3]. Long-term usage of topical steroids can cause skin side effects as well, including skin atrophy[11]. Animal studies have confirmed that topical HQ caused obvious skin irritation[12]. The molecular and cellular mechanisms mediating HQ-induced skin irritation remain largely unknown. Pharmacological blockage or genetic ablation of TRPA1 can reduce the acute response caused by many painful or irritating substances[15, 16, 20, 21]. Local pharmacological block of TRPA1 may provide an efficient way to reduce the skin irritation caused by HQ, thereby improving patients’ compliance when treated with HQ-containing skin therapeutics

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call